This activity is expired and is no longer available for CME credit.


The Latest on the Checkpoint Inhibitor Revolution in Advanced Melanoma: Focus on Long-term Outcomes and Brain Metastases

Author(s)/Faculty: Sanjiv S. Agarwala, MD; Hussein A. Tawbi, MD, PhD
Release Date: 5/1/2019Expiration Date: 4/30/2020
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
For patients diagnosed with metastatic melanoma, the lifetime incidence of brain metastasis is more than 50% and is associated with a poor prognosis. The approval and integration of immune checkpoint inhibitors for the treatment of patients with advanced melanoma has provided considerable clinical benefit and prolonged overall survival for a disease that has a historically poor prognosis. Furthermore, the use of immune checkpoint inhibitors in the adjuvant setting has prevented melanoma recurrence and led to US Food and Drug Administration approval for this indication. During this recorded CME symposium, experts in the field discuss the utilization of checkpoint inhibitors for the treatment of metastatic melanoma, with a focus on long-term outcomes and their emerging role for the management of patients with metastatic melanoma to the brain. Expert guidance for treatment selection as well as the identification and management of therapy-associated adverse events will be provided through the presentation of a clinical case of a patient suffering from advanced melanoma with brain metastasis.